As mentioned above, CD8+TRM‐like cells always exhibit exhaustion and dysfunction in tumors, promoting they as promising targets for ICB therapy to enhance tumor‐specific CD8+T cell responses [20, 23–28]. Here, CD8A is linked to neoplasm.